MedPath

Safety and Pharmacokinetic Characteristics of DP-R206(Vitamin D3) in Healthy Adult Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Registration Number
NCT01577849
Lead Sponsor
Alvogen Korea
Brief Summary

The purpose of this study is to compare the pharmacokinetic characteristics of DP-R206 (150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) and Vitamin D3 (24,000 IU Vitamin D3 , qd) after oral administration in healthy adult volunteers.

Detailed Description

The number of patient is thirty-six. Patients were randomly assigned either a Vitamin D3 tablet(24,000 IU Vitamin D3, qd) first, DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) Second or DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) first, Vitamin D3 tablet(24,000 IU Vitamin D3 , qd) second.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • 20 to 55 years of healthy volunteers
Exclusion Criteria
  • Hypersensitivity Reaction about Ibandronate or other drugs(aspirin, antibiotics)

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Vitamin D3Vitamin D3-
DP-R206DP-R206-
Primary Outcome Measures
NameTimeMethod
Composite of pharmacokinetics24, -18, -12, -6, 0(predose), 1, 4, 6, 8, 10, 16, 24, 36, 48, 72, 96, 120 hours post-dose

Cmax, AUClast

Secondary Outcome Measures
NameTimeMethod
Composite of pharmacokinetics24, -18, -12, -6, 0(predose), 1, 4, 6, 8, 10, 16, 24, 36, 48, 72, 96, 120 hours post-dose

AUCinf, tmax, t½β

Trial Locations

Locations (1)

Chonbuk national University Hospital

🇰🇷

Jeonju, Chonbuk, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath